analiza aiqbench
Vijay Pande's pivot from managing a $4 billion biotech practice at a16z to launching the smaller, AI-native VZVC highlights a strategic shift toward concentrated bets and heavy reliance on artificial intelligence for operational efficiency. The core narrative centers on how AI is transforming biology from a discovery-based field into an engineering discipline, while simultaneously addressing the critical challenge of data fragmentation in medical research. This transition underscores the industry's move away from high-volume, low-impact investing toward targeted applications where machine learning can effectively model complex biological systems.
‘We’re not doing 30 bets a year’: Vijay Pande on betting small after running $4B at a16z

Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.
It used to be that Vijay Pande was better known in academic circles than investor circles. That changed pretty abruptly a dozen years ago, when Marc Andreessen and Ben Horowitz — who’d spent their firm’s first five years explicitly avoiding healthcare and life sciences — decided the category was worth betting on after all and handed the keys to Pande. At the time, he was a Stanford chemistry professor who was best known for building Folding@home, the distributed-computing project that turned millions of home PCs into a supercomputer for disease research. Over the next decade-plus, he grew a16z’s bet into a practice managing close to $4 billion. So it was somewhat unexpected when in June of last year, Pande walked away from it all to start something much smaller. In fact, his new firm, VZVC, co-founded with longtime investor Zach Werner, is built around a handful of concentrated bets a year rather than dozens, it has no associates, and it relies heavily on AI for its day-to-day operations. To learn more about Pande’s hard pivot, we talked with him this week about why he’s making just a handful…
Extras afișat conform termenilor RSS ai publicației · 188 cuvinte · textul integral și figurile sunt pe site-ul publicației
Subiecte conexe

As Anthropic suspends access to new models, India debates its AI future
TechCrunch · 14 iun. 2026

Edward Thorp, The Man Who Beat The Odds
Quantum Zeitgeist · 5 sept. 2026

World Models and Yann LeCun’s Bet Against Large Language Models
Quantum Zeitgeist · 17 iul. 2026

Bluesky’s new CEO wants a big tent, not a bubble
The Verge · 3 aug. 2026